Business Context and Reporting Period
Company: Myomo, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 21, 2021
Reporting Period: Specific event date (January 21, 2021); not a periodic financial report.
Key Financial Metrics and Agreements
This filing details material definitive agreements rather than periodic financial performance. Key financial terms include:
- Joint Venture Investment: Partners committed to invest a minimum of $8 million and up to $20 million in the new China-based joint venture over five years.
- Upfront License Fee: Myomo is entitled to receive an upfront fee of $2.5 million under the Technology License Agreement.
- Purchase Commitment: The Joint Venture has agreed to an escalating purchase commitment for a minimum of $10.75 million in MyoPro Control System Units over ten years.
- Ownership Stake: Myomo will own a minimum 19.9% stake in the joint venture.
- Services Agreement: A new agreement with Geauga Rehabilitation Engineering, Inc. involves a base fee per unit for fabrication services, subject to minimum volume guarantees.
Note: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes and Strategic Developments
The primary material change is the entry into two significant agreements on January 21, 2021:
- China Joint Venture: Formation of "Jiangxi Myomo Medical Assistive Appliance Co., Ltd." with Beijing Ryzur Medical Investment Co., Ltd. and Chinaleaf Capital Management Co., Ltd. to manufacture and sell products in Greater China.
- Manufacturing Services: Execution of a Fabrication and Services Agreement with Geauga Rehabilitation Engineering, Inc., effective retroactively to January 1, 2021, to handle central fabrication and services.
Outlook, Risks, and Contingencies
Conditions Precedent:
- The establishment of the Joint Venture is subject to governmental filings and approvals in China.
- The purchase commitment of $10.75 million is subject to receipt of regulatory approvals necessary to permit sales in the Greater China territory.
- Payment of the $2.5 million license fee and technology transfer requires the completion of certain milestones, expected before the end of 2021.
Agreement Terms:
- The Technology License Agreement and Trademark License Agreement are contemplated for a ten-year term.
- The Services Agreement with Geauga Rehabilitation Engineering is non-exclusive and remains in effect for one year, with provisions for good faith negotiation for extension or termination upon 90 days' written notice.
Investor Verification Checklist
- Verify the status of required governmental filings and regulatory approvals in China for the Joint Venture.
- Confirm the specific milestones required to trigger the $2.5 million upfront license fee payment.
- Review the full text of Exhibit 10.1 (Equity Joint Venture Contract) and Exhibit 10.2 (Fabrication and Services Agreement) for detailed terms not summarized in the 8-K.
- Monitor the timeline for the completion of milestones expected before the end of 2021.